<![CDATA[Relapsed/Refractory Multiple Myeloma: Interpreting MonumenTAL-3 Efficacy and Safety Findings]]>

<![CDATA[Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma ]]>

<![CDATA[BCMA Biology, Mechanisms of Action, and Unmet Needs in Relapsed/Refractory Multiple Myeloma]]>

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Conditions : Relapsed or Refractory Multiple Myeloma Interventions : Biological: AZD4045; Drug: Daratumumab; Drug: Aldesleukin Sponsors : As

CAR-T in Relapsed/Refractory Multiple Myeloma

Conditions : Multiple Myeloma Refractory; Multiple Myeloma in Relapse Interventions : Biological: CAR-T Sponsors : Dr. Zaineb Akram Recruiti

<![CDATA[Isatuximab Wins FDA Approval, Becoming Second Subcutaneous Anti-CD38 for Multiple Myeloma]]>

<![CDATA[Pharmacist-Led Workflows Support Safe Outpatient BiTE Therapy in Multiple Myeloma]]>